PL3380522T3 - Cząsteczki przeciwciał wobec april i ich zastosowania - Google Patents

Cząsteczki przeciwciał wobec april i ich zastosowania

Info

Publication number
PL3380522T3
PL3380522T3 PL16810195.4T PL16810195T PL3380522T3 PL 3380522 T3 PL3380522 T3 PL 3380522T3 PL 16810195 T PL16810195 T PL 16810195T PL 3380522 T3 PL3380522 T3 PL 3380522T3
Authority
PL
Poland
Prior art keywords
applications
antibody molecules
molecules against
against april
april
Prior art date
Application number
PL16810195.4T
Other languages
English (en)
Inventor
James R. Myette
Zachary Holmes Shriver
Karthik Viswanathan
Andrew M. WOLLACOTT
Hedy ADARI-HALL
Boopathy Ramakrishnan
Gregory Babcock
Original Assignee
Visterra, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra, Inc. filed Critical Visterra, Inc.
Publication of PL3380522T3 publication Critical patent/PL3380522T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
PL16810195.4T 2015-11-25 2016-11-23 Cząsteczki przeciwciał wobec april i ich zastosowania PL3380522T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562259897P 2015-11-25 2015-11-25
US201662313684P 2016-03-25 2016-03-25
US201662399087P 2016-09-23 2016-09-23
US201662422848P 2016-11-16 2016-11-16
PCT/US2016/063518 WO2017091683A1 (en) 2015-11-25 2016-11-23 Antibody molecules to april and uses thereof

Publications (1)

Publication Number Publication Date
PL3380522T3 true PL3380522T3 (pl) 2024-03-25

Family

ID=57543212

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16810195.4T PL3380522T3 (pl) 2015-11-25 2016-11-23 Cząsteczki przeciwciał wobec april i ich zastosowania

Country Status (28)

Country Link
US (9) US20170145086A1 (pl)
EP (2) EP3380522B1 (pl)
JP (4) JP2019506363A (pl)
KR (2) KR102747820B1 (pl)
CN (3) CN109089419B (pl)
AU (2) AU2016361488B2 (pl)
BR (1) BR112018010673A8 (pl)
CA (1) CA3006058A1 (pl)
CL (2) CL2018001372A1 (pl)
CO (1) CO2018006461A2 (pl)
DK (1) DK3380522T5 (pl)
ES (1) ES2970864T3 (pl)
FI (1) FI3380522T3 (pl)
HK (1) HK1254337A1 (pl)
HR (1) HRP20231578T1 (pl)
HU (1) HUE064791T2 (pl)
IL (2) IL313508A (pl)
LT (1) LT3380522T (pl)
MA (1) MA43308A (pl)
MX (2) MX2018006385A (pl)
MY (1) MY197345A (pl)
PL (1) PL3380522T3 (pl)
PT (1) PT3380522T (pl)
SA (1) SA518391659B1 (pl)
SG (1) SG11201804309PA (pl)
SI (1) SI3380522T1 (pl)
WO (1) WO2017091683A1 (pl)
ZA (1) ZA201803366B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210340266A1 (en) * 2008-10-09 2021-11-04 Visterra, Inc. Antibody molecules to april and uses thereof
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CN106029653A (zh) 2014-01-31 2016-10-12 达纳-法伯癌症研究所股份有限公司 二氨基嘧啶苯砜衍生物及其用途
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩並三唑並二氮雜環庚三烯及其用途
CR20180199A (es) 2015-09-11 2018-05-25 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas
CN109089419B (zh) * 2015-11-25 2024-03-01 威特拉公司 April的抗体分子及其应用
RU2742035C2 (ru) 2015-11-25 2021-02-01 Дана-Фарбер Кэнсер Инститьют, Инк. Бивалентные ингибиторы бромодоменов и пути их применения
SG11202106452YA (en) * 2018-12-24 2021-07-29 Visterra Inc Methods for identifying epitopes and paratopes
MX2021009975A (es) * 2019-02-22 2021-12-10 Memorial Sloan Kettering Cancer Center Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer.
CN110522902B (zh) * 2019-09-25 2022-10-11 南京农业大学 一种用于建立慢性肾病模型的组合物及其应用
AR120884A1 (es) * 2019-12-24 2022-03-23 Dizal Jiangsu Pharmaceutical Co Ltd Anticuerpos anti-fgfr2b
IL296358A (en) * 2020-03-13 2022-11-01 Janssen Biotech Inc Materials and methods for modulating delta chain mediated immunity
PE20230494A1 (es) 2020-05-08 2023-03-23 Alpine Immune Sciences Inc Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas
MX2022016591A (es) 2020-06-24 2023-04-20 Visterra Inc Moléculas de anticuerpo contra april y usos de las mismas.
WO2022081716A1 (en) * 2020-10-13 2022-04-21 Accubit LLC - Biotechnology Methods of treating iga nephropathy with thiol-containing molecules
AU2021372463A1 (en) 2020-10-28 2023-06-22 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
CN112730851B (zh) * 2021-03-31 2021-06-22 南京立顶医疗科技有限公司 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒
EP4333889A4 (en) * 2021-05-04 2025-11-12 Immunorizon Ltd Anti-NKG2D antibodies and their uses
IL308336A (en) 2021-05-07 2024-01-01 Alpine Immune Sciences Inc Methods of dosing and treatment with TACI-FC modulatory fusion protein
KR20240021179A (ko) * 2021-05-14 2024-02-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 키메라 폴리펩티드 및 사용 방법
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
JP2025514142A (ja) 2022-04-25 2025-05-02 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用
JP2025535041A (ja) 2022-10-04 2025-10-22 アルパイン イミューン サイエンシズ インコーポレイテッド 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質
CN119930816A (zh) * 2023-11-02 2025-05-06 广东菲鹏制药股份有限公司 抗cd39人源化抗体或其抗原结合片段及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69330523D1 (de) 1992-08-21 2001-09-06 Vrije Universiteit Brussel Bru Immunoglobuline ohne leichte ketten
AU759717B2 (en) 1997-09-12 2003-04-17 Apoxis Sa April- a novel protein with growth effects
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
IL150755A0 (en) * 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
JP2004537290A (ja) 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
JP2008505607A (ja) 2004-01-29 2008-02-28 ジェネンテック・インコーポレーテッド Ｂｃｍａの細胞外ドメインの変異体とその使用法
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
ATE500275T1 (de) * 2005-09-26 2011-03-15 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
US8852591B2 (en) * 2007-03-27 2014-10-07 Zymogenetics, Inc. Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
ES2400107T3 (es) * 2007-10-22 2013-04-05 Merck Serono S.A. IFN-beta sencillo fusionado a un fragmento Fc de lgG mutado
JP5902478B2 (ja) * 2008-05-01 2016-04-13 ザイモジェネティクス， インコーポレイテッド 血清中のＢＬｙＳ／ＡＰＲＩＬヘテロ三量体レベルおよび診断方法における使用
US20210340266A1 (en) 2008-10-09 2021-11-04 Visterra, Inc. Antibody molecules to april and uses thereof
PL2403528T3 (pl) * 2009-03-02 2017-08-31 Aduro Biotech Holdings, Europe B.V. Przeciwciała przeciwko ligandowi indukującemu proliferację (APRIL)
EP2488200A4 (en) 2009-10-14 2013-06-12 Merck Sharp & Dohme APRIL ANTAGONISTS AND METHOD FOR THEIR USE
SI2506871T1 (sl) * 2009-11-30 2016-12-30 Janssen Biotech, Inc. Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
CA2810465C (en) * 2010-09-16 2018-10-02 Baliopharm Ag Anti-hutnfr1 antibody
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
DK3424953T3 (en) * 2011-06-06 2020-11-02 Novo Nordisk As Terapeutiske antistoffer
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
CN105392801A (zh) * 2013-03-15 2016-03-09 比奥根Ma公司 使用抗αvβ5抗体治疗和预防急性肾损伤
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
PL3065774T3 (pl) * 2013-11-06 2021-12-13 Janssen Biotech, Inc Przeciwciała anty-ccl17
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
WO2016113368A1 (en) 2015-01-15 2016-07-21 Universite Grenoble Alpes Anti april (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer
CN109089419B (zh) * 2015-11-25 2024-03-01 威特拉公司 April的抗体分子及其应用
CN105390742A (zh) * 2015-12-31 2016-03-09 石家庄圣泰化工有限公司 高电压锂离子电池电解液及其制备方法及应用
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
MX2022016591A (es) 2020-06-24 2023-04-20 Visterra Inc Moléculas de anticuerpo contra april y usos de las mismas.
US20230383010A1 (en) 2022-02-07 2023-11-30 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
JP2025514142A (ja) 2022-04-25 2025-05-02 ビステラ， インコーポレイテッド Ａｐｒｉｌに対する抗体分子およびその使用

Also Published As

Publication number Publication date
IL259585A (en) 2018-07-31
CN109089419A (zh) 2018-12-25
CO2018006461A2 (es) 2018-08-31
SG11201804309PA (en) 2018-06-28
JP2021184740A (ja) 2021-12-09
EP3380522A1 (en) 2018-10-03
PT3380522T (pt) 2024-02-14
WO2017091683A1 (en) 2017-06-01
KR20180091849A (ko) 2018-08-16
KR20250008787A (ko) 2025-01-15
BR112018010673A2 (pt) 2018-11-13
AU2023201698A1 (en) 2023-04-20
SA518391659B1 (ar) 2022-12-13
US20170145086A1 (en) 2017-05-25
HRP20231578T1 (hr) 2024-03-15
LT3380522T (lt) 2024-02-26
US12091451B2 (en) 2024-09-17
NZ742879A (en) 2025-06-27
NZ782606A (en) 2025-06-27
RU2018122452A3 (pl) 2020-05-13
HUE064791T2 (hu) 2024-04-28
US11136385B2 (en) 2021-10-05
JP2019506363A (ja) 2019-03-07
EP4285923A2 (en) 2023-12-06
CL2024000276A1 (es) 2024-08-30
EP4285923A3 (en) 2024-03-06
DK3380522T5 (da) 2024-09-30
MX2024010175A (es) 2024-08-27
WO2017091683A8 (en) 2022-12-15
CN118027201A (zh) 2024-05-14
ZA201803366B (en) 2025-09-25
CL2018001372A1 (es) 2018-11-23
ES2970864T3 (es) 2024-05-31
IL313508A (en) 2024-08-01
US20190330326A1 (en) 2019-10-31
NZ782617A (en) 2025-06-27
AU2016361488B2 (en) 2022-12-22
IL259585B2 (en) 2024-11-01
MY197345A (en) 2023-06-14
US10954296B2 (en) 2021-03-23
BR112018010673A8 (pt) 2019-02-26
KR102747820B1 (ko) 2024-12-27
US10385123B2 (en) 2019-08-20
US20200317770A1 (en) 2020-10-08
US10981982B2 (en) 2021-04-20
US20200299376A1 (en) 2020-09-24
US20210032324A1 (en) 2021-02-04
IL259585B1 (en) 2024-07-01
JP7029018B2 (ja) 2022-03-02
US20220235124A1 (en) 2022-07-28
SI3380522T1 (sl) 2024-02-29
US20190092851A1 (en) 2019-03-28
US10968270B2 (en) 2021-04-06
CN109089419B (zh) 2024-03-01
JP2022068288A (ja) 2022-05-09
DK3380522T3 (da) 2024-01-22
FI3380522T3 (fi) 2024-01-16
RU2018122452A (ru) 2019-12-25
AU2016361488A1 (en) 2018-06-14
US20250066464A1 (en) 2025-02-27
JP2024073611A (ja) 2024-05-29
MX2018006385A (es) 2019-09-11
US20200331995A1 (en) 2020-10-22
HK1254337A1 (zh) 2019-07-19
CN118420760A (zh) 2024-08-02
MA43308A (fr) 2018-10-03
EP3380522B1 (en) 2023-11-08
CA3006058A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
PL3380522T3 (pl) Cząsteczki przeciwciał wobec april i ich zastosowania
IL259987A (en) Antibody molecules to pd-1 and uses thereof
PL3383916T3 (pl) Przeciwciała anty-cd73 i ich zastosowania
PL3280441T3 (pl) Przeciwciała przeciwko sortilinie i sposoby ich stosowania
IL262095A (en) Anti-pacap antibodies and uses thereof
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
IL256416B (en) Multispecific antigen-binding molecules and uses thereof
PL3148579T3 (pl) Przeciwciała anty-gitr i sposoby ich zastosowania
DK3116909T3 (da) Antistofmolekyler til lag-3 og anvendelser deraf
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
PL3265448T3 (pl) Proleki riluzolu i ich zastosowanie
IL280863A (en) Autotaxin inhibitors and uses thereof
PL3274370T3 (pl) Przeciwciała anty-ceacam6 i ich zastosowania
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
HUE054339T2 (hu) CD73-ra specifikus kötõmolekulák és alkalmazásaik
DK3265575T3 (da) Cd20-bindende molekyler og anvendelser deraf
HUE045065T2 (hu) TIM-3 antitest molekulák és felhasználásaik
HUE045307T2 (hu) EGFRVIII-ellenes antitestek és alkalmazásaik
IL263273A (en) Anti-gitr antibodies and uses thereof
DK3532499T3 (da) ANTI-IL-33-antistoffer og anvendelser deraf
PL3402821T3 (pl) Przeciwciało wiążące psma i jego zastosowania
PL3359563T3 (pl) Receptory antygenów i ich zastosowania
IL271398A (en) Anti-l1-cam antibodies and uses thereof
DK3242685T3 (da) Cxcr4-bindende molekyler